Research at OLMC

Studies the Practice is involved in:

Garfield

Its aim is to determine in real-life practice the behaviour of newly-diagnosed patients with Atrial Fibrillation and at least one additional risk factor for stroke. It is an observational study which means that routine clinical practice is observed and no additional treatment is given to you as part of this study. Any treatment given follows the normal routine and is decided by the treating doctor.

EligibilityPatients aged 18 years and over
New diagnosis of Atrial Fibrillation, with at least one additional risk factor for stroke
DurationIt is anticipated that the total duration will be 6 years, allowing four years for recruitment and 2 years of follow up for the patient.

Taking partThe practice will write to patients who are eligible to take part in the study, giving details of the study and a consent form. Please take the time to read over the information sent to you and discuss it with your family. Only patients who want to be involved in the study and have given written consent will be included.

HEAT

This is a new study we are just commencing at the practice looking at the prevention of ulcer bleeding in patients taking aspirin. Aspirin can sometimes cause internal bleeding from ulcers. The study aims to find out whether this occurs more in patients who carry the bacteria Helicobactor (H.) pylori. This bacteria is present in the stomach of more than half the world’s population who usually do not know they have it because it seldom cause symptoms. The study will find out whether getting rid of the bacteria with antibiotics reduces the chance of ulcer bleeding

EligibilityPatients aged 60+
Taking aspirin
Not taking any anti-ulcer therapy or non-steroidal anti-inflammatory drugs
DurationThe trial will last for approximately 4 years

Taking partThe practice will write to patients who are eligible to take part in the study, giving details of the study and a consent form. Please take the time to read over the information sent to you and discuss it with your family. Only patients who want to be involved in the study and have given written consent will be included.

FAST

This study compares the effects of allopurinol with a newer treatment called “febuxostat”, which has been fully tested and recently approved for use across Europe.

EligibilityPatients aged 60+
Taking allopurinol
Have a diagnosis of gout
One additional risk factor
DurationThe trial will last for 3 years.

Taking partThe practice will write to patients who are eligible to take part in the study, giving details of the study and a consent form. Please take the time to read over the information sent to you and discuss it with your family. Only patients who want to be involved in the study and have given written consent will be included.